[go: up one dir, main page]

AR080426A1 - Composiciones y metodos para preparar polisacraidos de aloe - Google Patents

Composiciones y metodos para preparar polisacraidos de aloe

Info

Publication number
AR080426A1
AR080426A1 ARP110100086A ARP110100086A AR080426A1 AR 080426 A1 AR080426 A1 AR 080426A1 AR P110100086 A ARP110100086 A AR P110100086A AR P110100086 A ARP110100086 A AR P110100086A AR 080426 A1 AR080426 A1 AR 080426A1
Authority
AR
Argentina
Prior art keywords
aloe
mixture
powder
lyophilized
cancer
Prior art date
Application number
ARP110100086A
Other languages
English (en)
Inventor
Ivan E Danhof
Original Assignee
North Texas Medical Asociates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Texas Medical Asociates filed Critical North Texas Medical Asociates
Publication of AR080426A1 publication Critical patent/AR080426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
    • C08B37/0093—Locust bean gum, i.e. carob bean gum, with (beta-1,4)-D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from the seeds of carob tree or Ceratonia siliqua; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
    • C08B37/0096—Guar, guar gum, guar flour, guaran, i.e. (beta-1,4) linked D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from Cyamopsis Tetragonolobus; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Sustainable Development (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Un método para preparar un extracto de polimanano a partir de aloe en polvo liofilizado. El extracto de polimanano de la presente solicitud se utiliza también para formular una formulacion inyectable estéril para el tratamiento de uno o más tipos de cáncer, leucemias y linfomas, cáncer de prostata, cáncer de mamas, y cáncer de colon, enfermedades inmunes, en particular neoplasmas relacionados con el sistema inmune, síndrome de deficiencia inmune adquirida, y hepatitis C. Reivindicacion 1: Un método para preparar un polvo fino de un extracto de polimanano que comprende los pasos de: pesar una cantidad específica de un polvo de Aloe liofilizado, donde la cantidad se corrige por su contenido de humedad; disolver el polvo de Aloe liofilizado en agua desionizada para formar una solucion; agregar un solvente orgánico a la solucion para formar una primera mezcla; donde la proporcion entre solvente orgánico y agua desionizada es de por lo menos 2,5:1; permitir que la primera mezcla se sedimente durante por lo menos 8 horas; extraer un volumen específico de un sobrenadante de la primera mezcla y agregar un volumen en exceso de la solucion sobrenadante para formar una segunda mezcla; centrifugar la segunda mezcla; observar la presencia de un precipitado en la segunda mezcla; agregar una cantidad adicional del solvente orgánico a la primera mezcla si se observa la presencia de cualquier precipitado en la segunda mezcla; decantar el sobrenadante de la primera mezcla sifoneándolo, donde la decantacion se realiza solo si no se observa precipitado en la segunda mezcla; filtrar el precipitado de la primera mezcla usando un papel de filtro y un embudo con succion al vacío; recuperar el polvo del extracto de polimanano del embudo con succion raspándolo; dejar el polvo del extracto de polimanano en un matraz de liofilizacion tapado en un congelador durante por lo menos 8 horas; liofilizar el polvo del extracto de polimanano congelado en una liofilizadora; y moler el polvo del extracto de polimanano liofilizado en un molinillo hasta una textura muy fina. Reivindicacion 3: El método de la reivindicacion 1, donde el polvo de Aloe liofilizado se obtiene a partir de una especie de Aloe que se selecciona entre el grupo que consiste en: Aloe Vera, Aloe arborescens, Aloe aristata, Aloe dichotoma, Aloe nyeriensis, Aloe variegate, Aloe barbadensis, y Aloe wildii. Reivindicacion 5: El método de la reivindicacion 1, donde el polvo de Aloe liofilizado comprende polisacáridos de Aloe, donde los polisacáridos de Aloe comprenden uno o más polisacáridos de cadena corta, cadena media, cadena larga, o cadena muy larga, o cualquier combinacion de los mismos. Reivindicacion 6: El método de la reivindicacion 5, donde los polisacáridos de Aloe también comprenden azucares simples, que se seleccionan entre el grupo que consiste en: glucosa, manosa, arabinosa, y galactosa. Reivindicacion 7: El método de la reivindicacion 5, donde los polisacáridos de Aloe tienen un peso molecular dentro del rango entre 11.500 Daltons y más de 10.000.000 Daltons. Reivindicacion 12: El método de la reivindicacion 1, donde el polvo de Aloe liofilizado comprende por lo menos 3,5% de polisacáridos de Aloe con un peso molecular de 1.000.000 Daltons. Reivindicacion 13: El método de la reivindicacion 1, donde el polvo de Aloe liofilizado comprende por lo menos 2,4% de polisacáridos de Aloe con un peso molecular de 2.000.000 Daltons. Reivindicacion 17: La composicion de la reivindicacion 1, donde el polvo de Aloe liofilizado puede contener una o más especies residuales de bajo peso molecular, que se seleccionan entre el grupo que consiste en: glucosa, ácidos orgánicos, ácido láctico, ácidos málicos, ácidos cítricos, y ácido aspártico. Reivindicacion 20: El método de la reivindicacion 19, donde la composicion farmacéutica se utiliza en el tratamiento de una o más malignidades que se seleccionan entre el grupo que consiste en: leucemias y linfomas, cáncer de prostata, cáncer de mamas, y cáncer de colon, y para el tratamiento de uno o más trastornos del sistema inmune. Reivindicacion 23: La composicion de la reivindicacion 21, donde los uno o más conservantes farmacéuticos se seleccionan entre el grupo que consiste en: parabenos, ácido benzoico y sus sales, sustancias mercuriales, sales de amonio cuaternario, alcohol bencílico y otros alcoholes relacionados, y fenoles. Reivindicacion 34: La composicion de la reivindicacion 21, caracterizada porque la composicion se utiliza en el tratamiento de uno o más tipos de cáncer que se seleccionan entre el grupo que consiste en: leucemias y linfomas, cáncer de prostata, cáncer de mamas, y cáncer de colon.
ARP110100086A 2010-01-14 2011-01-11 Composiciones y metodos para preparar polisacraidos de aloe AR080426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29497010P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
AR080426A1 true AR080426A1 (es) 2012-04-11

Family

ID=44258987

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100086A AR080426A1 (es) 2010-01-14 2011-01-11 Composiciones y metodos para preparar polisacraidos de aloe

Country Status (3)

Country Link
US (4) US8604187B2 (es)
AR (1) AR080426A1 (es)
TW (1) TWI488631B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604187B2 (en) 2010-01-14 2013-12-10 North Texas Medical Associates Compositions and methods of aloe polysaccharides
RU2013100188A (ru) * 2010-07-23 2014-08-27 Наф Техас Мэдикэл Эсошиэйтс Антивирусные свойства алоэ вера и лечение синдрома приобретенного иммунодефицита (спид)
FI126211B (en) * 2012-11-09 2016-08-15 Montisera Ltd Wood-derived hemicelluloses for use in the treatment of lower urinary tract symptoms and disorders
US10456353B2 (en) 2014-04-17 2019-10-29 Conopco, Inc. Personal care compositions
JP2017511349A (ja) 2014-04-17 2017-04-20 ユニリーバー・ナームローゼ・ベンノートシヤープ パーソナルケア組成物用アロエベラ抽出物
WO2019077407A1 (en) * 2017-10-19 2019-04-25 Yale University INHIBITION OF THE ANDROGENIC RECEPTOR USING MEDICINAL PLANT EXTRACTS AND COMPOSITIONS THEREOF
CN116490198A (zh) * 2020-07-09 2023-07-25 尤尼根公司 用于调节免疫稳态的包含多糖和多酚的基于芦荟的组合物
CN114149512B (zh) * 2020-09-08 2023-11-14 戴垄生技股份有限公司 芦荟萃取物及其制备方法
CN116474106B (zh) * 2023-04-23 2024-11-29 北京荣祥再生医学研究所有限公司 一种药物载体组合物及其在制备药物中的应用、降糖药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118673A (en) * 1982-05-07 1992-06-02 Carrington Laboratories, Inc. Uses of aloe products
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US4735935A (en) * 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4851224A (en) * 1986-06-05 1989-07-25 Carrington Laboratories, Inc. Process for preparation of aloe products
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5902796A (en) * 1995-09-22 1999-05-11 Carrington Laboratories, Inc. Bioactive factors of aloe vera plants
US20030096378A1 (en) * 1997-10-10 2003-05-22 Univera Pharmaceuticals, Inc. Process for the preparation of immunomodulatory polysaccharides from aloe
US6133440A (en) 1997-10-10 2000-10-17 Univera Pharmaceuticals, Inc. Process for the preparation of immunomodulatory polysaccharides from aloe
US6083508A (en) * 1998-05-19 2000-07-04 Avalos; Ramiro Estrada Method of processing aloe leaves
CA2328092A1 (en) 1999-01-12 2000-07-20 Vito-Mannan Polysaccharide L.L.C. Method of isolating mucilaginous polysaccharides and uses thereof
US7196072B2 (en) * 2000-07-10 2007-03-27 University Of Mississippi High molecular weight polysaccharide fraction from Aloe vera with immunostimulatory activity
CN1362105A (zh) 2001-01-04 2002-08-07 杨孟君 纳米当归龙荟制剂药物及其制备方法
ES2376739T3 (es) * 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
WO2005112962A1 (en) 2004-05-21 2005-12-01 Shunichi Yagi Aloe powder, aloe juice, and method for producing the same
US20060084629A1 (en) * 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
EP2155147B1 (en) * 2007-05-11 2015-10-28 Woodcliff Skincare Solutions, Inc. Aloe preparation for skin enhancement
CN101070354B (zh) 2007-05-18 2010-04-07 中南大学 一种利用芦荟同时生产芦荟多糖粉、芦荟活性水的方法
CN101306012A (zh) 2008-06-19 2008-11-19 中国人民解放军第四军医大学 富含甘露糖的改性多糖在制备阻止结肠炎癌变的药物中的应用
US8604187B2 (en) 2010-01-14 2013-12-10 North Texas Medical Associates Compositions and methods of aloe polysaccharides
WO2012094010A1 (en) 2011-01-06 2012-07-12 North Texas Medical Associates Compositions and methods of aloe polysaccharides

Also Published As

Publication number Publication date
TWI488631B (zh) 2015-06-21
US8604187B2 (en) 2013-12-10
US10314858B2 (en) 2019-06-11
US10918659B2 (en) 2021-02-16
TW201143776A (en) 2011-12-16
US9649326B2 (en) 2017-05-16
US20110172181A1 (en) 2011-07-14
US20190255095A1 (en) 2019-08-22
US20140057867A1 (en) 2014-02-27
US20170246199A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AR080426A1 (es) Composiciones y metodos para preparar polisacraidos de aloe
RU2013127633A (ru) Композиции и способы полисахаридов алоэ
JP2014501777A5 (es)
Joseph et al. A galactomannan polysaccharide from Punica granatum imparts in vitro and in vivo anticancer activity
Nguyen et al. An investigation into the supramolecular structure, solubility, stability and antioxidant activity of rutin/cyclodextrin inclusion complex
WO2012116272A3 (en) Polymer conjugated protein micelles
Hwang et al. pH-Responsive robust polymer micelles with metal–ligand coordinated core cross-links
Lee et al. Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma
Sun et al. Supramolecular PEGylation of camptothecin for cancer therapy
Pudale et al. A histopathological study of non-malignant breast lesions.
Hong et al. Cancer cell preferential penetration and pH-responsive drug delivery of oligorutin
CN102134188A (zh) 四氢蒽醌类化合物Prisconnatacin及其制备方法和在制备抗肿瘤药物中的应用
ES2618938T3 (es) Compuestos de ácido bencenopolicarboxílico y su uso como fármacos
Su et al. Size transformable organic nanotheranostic agents for NIR-II imaging-guided oncotherapy
KR101436687B1 (ko) 매스틱 추출물을 포함하는 화장품 조성물 및 그 제조방법
US9655913B2 (en) Anti-esophageal cancer compound and method of use thereof
ZHANG Preparation of multifunctional targeting epirubicin liposomes and their efficacy in inhibiting brain glioma cells
Vahid et al. [Design and synthesis of a novel dendrosome and a PEGylated PAMAM dendrimer nanocarrier to improve the anticancer effect of turmeric [curcuma longa] curcumin]
LI et al. TF modiifed doxorubicin and Rg3 loaded liposome for gastric cancer targeting and therapy
LIN et al. Construction and in vitro and in vivo Preliminary Evaluation of Biotin-poloxamer Conjugate Polymeric Mi-celles for Epirubicin
Mitra et al. < The> protective effect of cell wall and cytoplasmic fraction of selenium enriched yeast on 1, 2-dimethylhydrazine-induced damage in liver
Özbey et al. Biosynthesis, Optimization and Characterization of Zinc Chloride Nanoparticles Using Sideritis sp. Extract
LI et al. Preparation and properties of docetaxel-loaded nanobubbles
ZHANG et al. Proton pump inhibitors and the pathophysiological mechanism of the risk of gastric cancer and its clinical researchs progress
ZHANG et al. Distribution of nesfatin-1/NUCB2 in the digestive system of humans and rodents

Legal Events

Date Code Title Description
FG Grant, registration